TY - JOUR
T1 - Publisher Correction
T2 - Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)
AU - Powles, Thomas
AU - Kockx, Mark
AU - Rodriguez-Vida, Alejo
AU - Duran, Ignacio
AU - Crabb, Simon J.
AU - van der Heijden, Michiel S.
AU - Szabados, Bernadett
AU - Pous, Albert Font
AU - Gravis, Gwenaelle
AU - Herranz, Urbano Anido
AU - Protheroe, Andrew
AU - Ravaud, Alain
AU - Maillet, Denis
AU - Mendez, Maria Jose
AU - Suarez, Cristina
AU - Linch, Mark
AU - Prendergast, Aaron
AU - van Dam, Pieter-Jan
AU - Stanoeva, Diana
AU - Daelemans, Sofie
AU - Mariathasan, Sanjeev
AU - Tea, Joy S.
AU - Mousa, Kelly
AU - Banchereau, Romain
AU - Castellano, Daniel
N1 - Publisher Copyright: © 2023, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2023/12
Y1 - 2023/12
N2 - Correction to: Nature Medicine. Published online 4 November 2019. In the version of this article initially published, under the Methods subsection “Trial design and patient population,” the dosing of atezolizumab was wrongly stated as “1,200 mg, three times weekly.” The correct dose is 1,200 mg, once every three weeks.
AB - Correction to: Nature Medicine. Published online 4 November 2019. In the version of this article initially published, under the Methods subsection “Trial design and patient population,” the dosing of atezolizumab was wrongly stated as “1,200 mg, three times weekly.” The correct dose is 1,200 mg, once every three weeks.
UR - http://www.scopus.com/inward/record.url?scp=85150419311&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41591-023-02312-9
DO - https://doi.org/10.1038/s41591-023-02312-9
M3 - Comment/Letter to the editor
C2 - 36944799
SN - 1078-8956
VL - 29
SP - 3271
JO - Nature medicine
JF - Nature medicine
IS - 12
ER -